发布求助
文献互助 智能选刊 最新文献

Klinicka Farmakologie a Farmacie最新文献

筛选
英文 中文
Analysis of Crohn´s disease pharmacotherapy in the child and adult population 儿童和成人克罗恩病药物治疗分析
Klinicka Farmakologie a Farmacie Pub Date : 2023-07-10 DOI: 10.36290/far.2023.009
M. Kolesárová, A. Vassová, D. Marcinčáková, J. Kyselovič, A. Gažová
{"title":"Analysis of Crohn´s disease pharmacotherapy in the child and adult population","authors":"M. Kolesárová, A. Vassová, D. Marcinčáková, J. Kyselovič, A. Gažová","doi":"10.36290/far.2023.009","DOIUrl":"https://doi.org/10.36290/far.2023.009","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43209968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risks of opioid use in the elderly with persistent pain 阿片类药物在老年持续性疼痛患者中的使用风险
Klinicka Farmakologie a Farmacie Pub Date : 2023-07-10 DOI: 10.36290/far.2023.013
Marek Lapka
{"title":"Risks of opioid use in the elderly with persistent pain","authors":"Marek Lapka","doi":"10.36290/far.2023.013","DOIUrl":"https://doi.org/10.36290/far.2023.013","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45722433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nejvýznamnější enzymy druhé fáze metabolismu léčiv: UDP-glukuronosyltransferázy a sulfotransferázy 药物代谢第二阶段最重要的酶：UDP葡萄糖醛酸基转移酶和磺基转移酶
Klinicka Farmakologie a Farmacie Pub Date : 2023-07-10 DOI: 10.36290/far.2023.008
Pavel Anzenbacher
{"title":"Nejvýznamnější enzymy druhé fáze metabolismu léčiv: UDP-glukuronosyltransferázy a sulfotransferázy","authors":"Pavel Anzenbacher","doi":"10.36290/far.2023.008","DOIUrl":"https://doi.org/10.36290/far.2023.008","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45321267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab-induced cardiotoxicity: a review 曲妥珠单抗诱导的心脏毒性：综述
Klinicka Farmakologie a Farmacie Pub Date : 2023-07-10 DOI: 10.36290/far.2023.011
Marek Lapka
{"title":"Trastuzumab-induced cardiotoxicity: a review","authors":"Marek Lapka","doi":"10.36290/far.2023.011","DOIUrl":"https://doi.org/10.36290/far.2023.011","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42277210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tirzepatid - a new hope in the treatment of obesity and a new antidiabetic drug 替西帕肽——治疗肥胖的新希望和一种新的降糖药
Klinicka Farmakologie a Farmacie Pub Date : 2023-07-10 DOI: 10.36290/far.2023.012
R. Prosecký, J. Vítovec
{"title":"Tirzepatid - a new hope in the treatment of obesity and a new antidiabetic drug","authors":"R. Prosecký, J. Vítovec","doi":"10.36290/far.2023.012","DOIUrl":"https://doi.org/10.36290/far.2023.012","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41425879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Switch of a patient with ulcerative colitis to subcutaneous infliximab for recurrent upper respiratory tract infections 治疗复发性上呼吸道感染的溃疡性结肠炎患者改用皮下英夫利昔单抗治疗
Klinicka Farmakologie a Farmacie Pub Date : 2023-07-10 DOI: 10.36290/far.2023.014
M. Konečný
{"title":"Switch of a patient with ulcerative colitis to subcutaneous infliximab for recurrent upper respiratory tract infections","authors":"M. Konečný","doi":"10.36290/far.2023.014","DOIUrl":"https://doi.org/10.36290/far.2023.014","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41623870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Limitations of idarucizumab efficacy in acute renal failure - a case report 依达鲁珠单抗治疗急性肾功能衰竭疗效的局限性——一例报告
Klinicka Farmakologie a Farmacie Pub Date : 2023-07-10 DOI: 10.36290/far.2023.015
J. Rychlíčková, T. Trávníček, Tereza Jelínková, J. Žák
{"title":"Limitations of idarucizumab efficacy in acute renal failure - a case report","authors":"J. Rychlíčková, T. Trávníček, Tereza Jelínková, J. Žák","doi":"10.36290/far.2023.015","DOIUrl":"https://doi.org/10.36290/far.2023.015","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46893144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug interactions of medications used in the therapy of erectile dysfunction with dietary supplements 用于治疗勃起功能障碍的药物与膳食补充剂的药物相互作用
Klinicka Farmakologie a Farmacie Pub Date : 2023-04-21 DOI: 10.36290/far.2023.003
J. Suchopár, Štěpán Suchopár, M. Prokeš
{"title":"Drug interactions of medications used in the therapy of erectile dysfunction with dietary supplements","authors":"J. Suchopár, Štěpán Suchopár, M. Prokeš","doi":"10.36290/far.2023.003","DOIUrl":"https://doi.org/10.36290/far.2023.003","url":null,"abstract":"Rostlinné přípravky, respektive z nich vyrobené doplňky stravy, mohou vést k lékovým interakcím podobně jako léky. Výrobci takových doplňků stravy však na případné lékové interakce neupozorňují. Inhibitory fosfodiesterázy typu 5 (iPDE5) jsou široce užívané léky, jejichž společnou vlastností je odbourávání cestou CYP3A4 a CYP3A5. Inhibitory a induktory těchto isoenzymů cytochromu P-450 vyvolávají různě závažné lékové interakce a pouze k některým z nich je možné v SPC dohledat doporučený management. Cílem článku je podat základní informaci o rostlinných přípravcích, které mají potenciál ovlivnit farmakokinetické vlastnosti a v některých případech patrně i účinnost a bezpečnosti iPDE5. Klíčová slova: inhibitory fosfodiesterázy typu 5, iPDE5, avanafil, sildenafil, tadalafil, udenafil, vardenafil, lékové interakce, rostlinné přípravky.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49453890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is new in the pharmacotherapy of benign prostatic hyperplasia 良性前列腺增生的药物治疗有什么新进展
Klinicka Farmakologie a Farmacie Pub Date : 2023-04-21 DOI: 10.36290/far.2023.002
J. Marenčák
{"title":"What is new in the pharmacotherapy of benign prostatic hyperplasia","authors":"J. Marenčák","doi":"10.36290/far.2023.002","DOIUrl":"https://doi.org/10.36290/far.2023.002","url":null,"abstract":"Benígna hyperplázia prostaty a následné symptómy dolných močových ciest sú závažným zdravotným problémom, ktorý postihuje milióny mužov. Existuje mnoho nezodpovedaných otázok vrátane úlohy zápalu, metabolickej dysfunkcie, obezity a environmentálnych faktorov v etiológii, ako aj úlohy terapeutických algoritmov pri prevencii a progresii ochorenia. V článku podávame prehľad súčasnej a aj novej farmakoterapie benígnej hyperplázie prostaty. Budúce liečebné snahy môžu využiť personalizovanejšie stratégie manažmentu tohto nezhubného ochorenia s významným negatívnym dopadom na kvalitu života starších mužov. Kľúčové slová: benígna hyperplázia prostaty, farmakoterapia, monoterapia, kombinovaná liečba, nové liečivá.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43753563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Flucloxacillin pharmacokinetic properties 氟氯唑西林的药代动力学特性
Klinicka Farmakologie a Farmacie Pub Date : 2023-04-21 DOI: 10.36290/far.2023.006
Vendula Kubíčková, V. Vojtova, K. Urbánek
{"title":"Flucloxacillin pharmacokinetic properties","authors":"Vendula Kubíčková, V. Vojtova, K. Urbánek","doi":"10.36290/far.2023.006","DOIUrl":"https://doi.org/10.36290/far.2023.006","url":null,"abstract":"Flukloxacilin je polosyntetické betalaktamové antibiotikum ze skupiny isoxazolylpenicilinů. Od oxacilinu se liší připojením jednoho atomu fluoru a chloru na benzenové jádro, což zlepšuje vstřebávání z GIT a prodlužuje jeho biologický poločas. Jeho biologická dostupnost je 54–79 %, distribuční objem 0,14 ± 0,14 l/kg, vazba na plazmatické bílkoviny dosahuje 92–95 %. Metabolizován je jen asi z 10 %, vylučuje se ze 75 % ledvinami glomerulární filtrací i tubulární sekrecí s poločasem 0,75–1,14 h. Dávkování se dle závažnosti stavu a charakteristik pacienta pohybuje od 500 mg každých 8 hodin p. o. až po 2 g co 4 h i. v., celková denní dávka by neměla překročit 12 g. Terapeutické monitorování by mohlo optimalizovat dávkování u pacientů se zvýšenou renální clearance a u onemocnění způsobených méně citlivými patogeny, mělo by být založeno na stanovení jeho volné frakce. Klíčová slova: flukloxacilin, farmakokinetika, dávkování, PKPD charakteristiky.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42482688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信